An advancement in 3D bioprinting of native-like skeletal muscle tissues has been made by scientists at the Terasaki Institute for Biomedical Innovation (TIBI). The key to the TIBI scientists’ approach lies in their specially formulated bioink, which contains microparticles engineered for sustained delivery of insulin-like growth factor-1 (IGF-1).
Click here for original story, New and improved bioink to enhance 3D bioprinted skeletal muscle constructs
Source: Phys.org